IL-17

2025

The 2025 Rheumatology Year in Review

Jack Cush, MD

The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.

Read Article
PSO.Palmoplantar.jpg

Advanced Practitioner Biologic Prescriptions for Psoriasis

Jack Cush, MD

Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA Dermatology reports APC drug spending trends in dermatology, with a focus on

Read Article
GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

2026 Resolutions (1.9.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

Read Article
guidelines.recommendations.jpg

Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis

Jack Cush, MD

Editor's note: This article was originally published April 22, 2025, and is being shared again as part of RheumNow's 'Best of 2025' series as we close out the year. Enjoy!

Read Article
hospital,surgery

Best of 2025: Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients

Jack Cush, MD

More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the setting of DMARDs use. A scoping review looked at numerous clinical practice guidelines/recommendations for the

Read Article
RheumNow Podcast square

Turkey Tryptophan (11.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?

Read Article
Study of 452 #PsA pts who failed 1st line TNFi Rx (LOE) - 275 Cycled to another TNFi vs 177 Swapped to an IL-17i. Higher Retention in Swap (78%) vs cycled (68%) PsA pts (p < 0.001) @12 mos (60 v 40%@3yrs). Tx failure predicted by cycling, Dz Activity, Rx year, axial & mixed https://t.co/VQLBlBEw4W
Dr. John Cush @RheumNow( View Tweet )
No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of 34 241 ipts Rx IL-17(R)Ai and 381 MACEs. MACE risk was not elevated (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitors. https://t.co/WcjgRhr8mj https://t.co/Gp54eLlXSI

Links:

Dr. John Cush @RheumNow( View Tweet )
IL-23 Blockade Goes Oral A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the IL-23R, is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies. https://t.co/MyqCjilYGL
Dr. John Cush @RheumNow( View Tweet )
Nerandomilast for ILD Dr. Mike Putman reports on abstract 1662 (Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial). #ACR25 https://t.co/J0e4SbVgFE https://t.co/dlOM700yVQ

Links:

Dr. John Cush @RheumNow( View Tweet )
syringe, pill, DMARD, Treatment, therapy

What should head-to-head studies in inflammatory arthritis teach us?

Janet Pope, MD, MPH, FRCPC

The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?

Read Article
acr_session2.jpeg

ACR25 Best Abstracts - Day 4

Jack Cush, MD

Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty.  Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!

Read Article
In a 5-year EHR-based cohort, PsO patients initiating IL-17i had significantly lower incidence of PsA/IA vs IL-23i, IL-12/23i, or TNFi. IL-17i reduced time with PsA/IA by 45% vs IL-23i, 61% vs IL-12/23i, and 74% vs TNFi. Further research need investigate if IL-17i may delay https://t.co/0PTbXZpLbu

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#ACR25 Clinical Review by Prof Coates @DrLauraCoates to be applied tomorrow! Early Diagnosis/Tx Abstr#2689 EHR study = IL-17i could prevent #PsA vs IL-23/TNFi Abstr#576 Oligo → Polyarthritis progression in women, no DMARD, enthesitis, dactylitis, nail psoriasis @RheumNow https://t.co/e1hCERpCNW

Links:

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Do biologics prevent PsA? Retro cohort analysis EHR through natural language processing 5 years trends PsO treated w/ IL-17i had lower incidence of PsA/IA than pts treated w/ IL-23i, IL-12/23i, or TNFi therapies Adjustment on several confounding Prospective data heavily https://t.co/W9MFaWNbWC

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj @synovialjoints Elaborate more on head to head trial in PsA , in a population who failed TNF biologic. @RheumNow #ACR25

Links:

Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )

52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA Primary ACR 50 16wks Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-> IZO 160 QW ACR50 50% 57% 51% ACR70 36% 42% 42% PASI100 55% 64% 58% MDA 47% 52% 47% No specific enthesitis data presented No new safety signal Next https://t.co/J18rSTmyze

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
#IL2 #Rx in active #SLE? Maybe 🤔 IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact. RCT of IL2i in #SLE gave a good dose response and improved TRegs. #ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We

Links:

Janet Pope @Janetbirdope( View Tweet )
ROC-SpA study assessed whether changing to an IL-17Ai was superior to rotating to a 2nd TNFi in axSpA pts who failed on a 1st TNFi At wk 24, no significant diff in ASAS40 rates bet the 2 groups IL-17Ai not superior to a 2nd TNFi Rotate or change? #ACR25 @Rheumnow AbsLB09 https://t.co/4EtNEFTSN9

Links:

sheila @RHEUMarampa( View Tweet )
Gladman et al. PsA patients treated with guselkumab in DISCOVER-2. Male patients had more radiographic progression. Males exhibit stronger relationship between early joint response and lower subsequent rates radiographic progression. @RheumNow #ACR25 Abstr#2345 https://t.co/TSNwesvPzj

Links:

Richard Conway @RichardPAConway( View Tweet )
Late breaking: secukinumab out-performs ustekinumab in PsA pt who have failed TNF therapy RCT of 119 pt 57.1% response at wk 28 in SEC 27% response at wk 28 in UST Numerically lower adverse events leading to d/c in SEC @RheumNow #ACR25 #ACRBest Abst LB06 https://t.co/wDxtscP2ku

Links:

Brian Jaros, MD @Dr_Brian_MD( View Tweet )

To be continued (or discontinued?): Abstract 2360: Compared to TNFi, IL-17i & JAKi users had 🔹 Higher odds of med switching <180 days 🔹 Shorter time to discontinuation @RheumNow #ACR25 #axSpA https://t.co/IOHaFSJqHn

Links:

Akhil Sood MD, MS @AkhilSoodMD( View Tweet )
Meta-analysis of 3 RCTs (n=1990) shows IL-17i offers comparable joint response but superior skin clearance vs adalimumab in biologic-naive PsA. IL-17i also had fewer discontinuations due to adverse events. Supports sequencing of biologics through different mechanisms of action in https://t.co/SJgFUMxWVb

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Heydari-Kamjani et al. TriNetX study. 28973 PsA patients. IL-17i and IL-23i lower rates stroke, MI, DVT/PE than TNFi. IL-12/23i higher rate of stroke vs TNFi. @RheumNow #ACR25 Abstr#2363 https://t.co/fNHaxyYPCP

Links:

Richard Conway @RichardPAConway( View Tweet )

Recent Blogs

Best of 2022: The Enthesitis Challenge in Psoriatic Arthritis

Robert Chao, MD
heel enthesitis spur calcaneal
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do!  Read Post

Best of 2022: Toss of a Coin - How do You Choose PsA Medication?

M. Elaine Husni, MD, MPH
Coin toss
When balancing all these disease domains, individual phenotypes, and comorbidities, sometimes treatment decisions can feel like tossing a coin. Fortunately, numerous guidelines have been published to help us do better than tossing a coin…or do they?  Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×